YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Medpace (MEDP) ended the recent trading session at $602.90, demonstrating a -2.84% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. On the other hand, the Dow…
In the latest trading session, Medpace (MEDP) closed at $622.11, marking a +1% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the t…
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a…
3 Market-Beating Stocks with Promising Prospects Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost alway…
CINCINNATI, September 22, 2026--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) ("Medpace") today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Comp…
In recent days, Medpace Holdings drew attention as analysts projected its upcoming quarterly earnings per share to rise 15.28% year over year alongside a 7.4% revenue increase. This combination of earnings and revenue growth expectations h…
Medpace Holdings (MEDP) is back in focus as investors watch for its upcoming earnings report, with expectations for higher earnings per share and revenue shaping near term sentiment around the contract research group. Recent trading has be…
In the latest trading session, Medpace (MEDP) closed at $624.20, marking a +1.94% move from the previous day. The stock's change was more than the S&P 500's daily gain of 1.49%. At the same time, the Dow added 0.71%, and the tech-heavy Nas…
1 Volatile Stock with Solid Fundamentals and 2 Facing Challenges Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out eve…
Medpace (MEDP) closed the most recent trading day at $595.41, moving +1.34% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.48% for the day. Elsewhere, the Dow saw a downswing of 0.29%, while…
Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA) As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the drug development inputs & services industry, includin…
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors? We'll need to take a closer look…
2 Healthcare Stocks with Competitive Advantages and 1 We Question Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong finan…
Revvity, Inc. RVTY is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup. The counterweight is valuation. RVTY alr…
Innventure, Inc. Bruce Brown Appointed as Chairman of the Innventure Board Catriona Fallon Publicly Named as Audit Committee Chair Dr. William Grieco Assumes CEO and Director Roles Effective September 1, 2026 Announces Ongoing Search for N…
A month has gone by since the last earnings report for Teladoc (TDOC). Shares have lost about 3.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Tela…
Medpace (MEDP): Buy, Sell, or Hold Post Q2 Earnings? Medpace currently trades at $610.21 and has been a dream stock for shareholders. It's returned 238% since August 2021, more than tripling the S&P 500's 70.1% gain. The company has also b…
Medpace stock is back below a buy point of 628.92. The medical research contractor delivered an earnings beat for its second quarter. Continue Reading
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer…
August J. Troendle, President & CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), sold 15,978 shares of common stock in a transaction valued at $10.0 million. SEC Form 4 filing Transaction summary Metric Value Transaction value $10.0 million Sh…
Veeva Systems VEEV is scheduled to report second-quarter fiscal 2027 results on Aug. 26, after the market close. In the last reported quarter, the company's earnings per share (EPS) of $2.24 topped the Zacks Consensus Estimate by 5.16%. Ov…
It has been about a month since the last earnings report for Medpace (MEDP). Shares have added about 1.1% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading…
Charles River Laboratories International, Inc. CRL shares have risen 33.3% over the past four weeks. The move has lifted expectations just as operating trends are beginning to improve.Zacks Investment Research Image Source: Zacks Investmen…
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. After a 233.1% total return over the past five years, Medpace Holdings now trades in a zone where the Discounted Cash F…
In the past few days, Medpace Holdings reported Q2 results that exceeded analyst revenue expectations and raised its full-year revenue guidance. The company also delivered the fastest revenue growth and largest guidance increase among its…
During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fu…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Medpace Holdings Stock Is Back in Focus After Q2 Results Medpace Holdings (MEDP) drew fresh attention after reporting Q2 earnin…
Drug Development Inputs & Services Stocks Q2 Recap: Benchmarking Medpace (NASDAQ:MEDP) As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the drug development inputs & service…
2 Mid-Cap Stocks Worth Your Attention and 1 We Question Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporat…
Haemonetics Corporation HAE posted first-quarter fiscal 2027 adjusted earnings of $1.14 per share, up 3.6% year over year. The figure beat the Zacks Consensus Estimate by 6.5%. On a GAAP basis, earnings per share were 72 cents compared wit…
National Vision Holdings, Inc. EYE posted second-quarter 2026 adjusted earnings of 25 cents per share, up 38.9% year over year. The bottom line beat the Zacks Consensus Estimate by 47.1%. Quarterly net revenues rose 2.5% year over year to…
Bio-Techne Corporation TECH reported adjusted earnings per share of 52 cents for the fourth quarter of fiscal 2026, which dropped 1.9% year over year and came in line with the Zacks Consensus Estimate. The quarter's adjustments eliminated…
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2…
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries. Another thing that can drive…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is ALX Oncology Holdings Inc. (ALXO) one of those stocks right now? A quick glance at the company's year…